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Background: The mechanistic target of rapamycin (mTOR) has been implicated in driving tumor biology in multiple malignancies,
including urothelial carcinoma (UC). We investigate how mTOR and phosphorylated mTOR (pmTOR) protein expression correlate with
chemoresponsiveness in the tumor and its microenvironment at ﬁnal pathologic staging after neoadjuvant chemotherapy (NAC).
Methods: A single-institution retrospective analysis was performed on 62 patients with cT2–4Nany UC undergoing NAC followed by
radical cystectomy. Diagnostic (transurethral resection specimens, TURBT) and postchemotherapy radical cystectomy specimens were
evaluated for mTOR and pmTOR protein expression using immunohistochemistry of the tumor, peritumoral stroma, and normal surrounding
stroma. Protein expression levels were compared between clinical and pathologic stage. Whole transcriptome analysis was performed to
evaluate mRNA expression relative to mTOR pathway activation.
Results: Baseline levels of mTOR and pmTOR within TURBT specimens were not associated with clinical stage and response to
chemotherapy overall. Nonresponders with advanced pathologic stage at cystectomy (ypT2–4/ypTanyNþ) had signiﬁcantly elevated mTOR tumor
staining (P ¼ 0.006) and a sustained mTOR and pmTOR staining in the peritumoral and surrounding normal stroma (NS). Several genes relevant
to mTOR activity were found to be up-regulated in the tumors of nonresponders. Remarkably, complete responders at cystectomy (ypT0) had
signiﬁcant decreases in both mTOR and pmTOR protein expression in the peritumoral and normal stroma (P ¼ 0.01–0.03).rolonc.2018.03.016
uthors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
rg/licenses/by-nc-nd/4.0/).
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B.R. Winters et al. / Urologic Oncology: Seminars and Original Investigations 36 (2018) 342.e7–342.e14342.e8Conclusions: Our results suggest that mTOR pathway activity is increased in tumor and sustained in its microenvironment in patients
with adverse pathologic ﬁndings at cystectomy. These ﬁndings suggest the relevance of targeting this pathway in bladder cancer. r 2018
The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The mechanistic target of rapamycin (mTOR) is a
major regulator of fundamental biological processes
including cell growth and protein synthesis, and is
commonly deregulated in human cancers including uro-
thelial carcinoma (UC) [1]. mTOR has been recognized
as a cytoplasmic kinase controlling translation, autoph-
agy, and protein degradation [2] but when dysregulated,
can be associated with tumorigenesis, disease recurrence,
and worsened overall survival [3]. Further, there is
evidence that the mTOR pathway can serve as compen-
satory mechanism for cancers treated with targeted
therapies, possessing both cell-autonomous and nonau-
tonomous resistance capabilities [4].
Emerging evidence has demonstrated that the tumor
microenvironment is a complex ecosystem of extracellu-
lar matrix and stromal growth factors with signiﬁcant
pathway crosstalk and cellular plasticity, each of which
may promote tumor progression and treatment resistance
[5,6]. One mechanism by which the tumor microenviron-
ment supports tumor growth is the DNA damage response
—a complex and coordinated, evolutionary mechanism
which allows an organism to repair DNA damage at a
constant rate [7]. During UC treatment, however, the
genotoxic stress induced by “standard of care,” platinum-
based chemotherapy impacts both tumor and ﬁbroblasts
in the surrounding stroma. This genotoxic stress then
liberates the DNA damage secretory program involving
cytokines, growth factors, and proteases to augment
chemoresistance [7]. Subsequently, malignancies can
then utilize alternate signaling pathways, including can-
onical WNT-signaling [8], as escape mechanisms to
abrogate chemotherapeutic response. Interestingly,
mTOR inhibition has shown some efﬁcacy in limiting
inﬂammatory cytokines (e.g., IL-6) and NF-kB transcrip-
tional activity, the latter of which is thought to be a main
regulator of WNT signaling in response to DNA damage
[8,9]. Genomic subtyping of bladder cancer tumors
[10,11] has shed insight into treatment sensitivity, yet
molecular evidence points toward a “ﬁeld-change effect,”
[12] suggesting that targeting the tumor alone may be
insufﬁcient and an improved understanding of the tumor
microenvironment in UC is required.
In this study, we evaluate mTOR protein expression in
both the tumor and its microenvironment in UC, thereby
assessing its inﬂuence on pathological outcomes and
response to neoadjuvant chemotherapy (NAC). We reveal
that mTOR protein expression signiﬁcantly correlates withmore aggressive pathology after NAC and is sustained
relative to increasing stage strata. In patients who experi-
ence a complete response to NAC, we ﬁnd minimal mTOR
protein expression in the tissue stroma. These results
support the relevance of mTOR activity in the UC tumor
microenvironment.2. Materials and methods
2.1. Patient population
All patients undergoing radical cystectomy for UC after
NAC at a single institution were retrospectively reviewed
under an IRB approved study (2003–2011; UW/FHCRC).
The analysis was limited to those patients with available
pre-NAC, transurethral resection specimens (TURBT) (N ¼
62). We focused on patients with ≥ clinical T2 disease at
diagnosis [13]. Pre-NAC samples were acquired from
outside and institutional pathology laboratories, followed
by matching with ﬁnal pathologic, radical cystectomy
specimens from our institution. Clinical and pathologic
variables of the cohort included age, sex, race, histology,
chemotherapy regimen, clinical, and pathologic staging. For
evaluating the effects of chemotherapy relative to mTOR
protein expression, we grouped patients into complete
responders (ypT0), partial responders (ypTa/ypTIS/ypT1),
and nonresponders (ypT2–4/ypTanyNþ) at cystectomy. All
staging refers to the AJCC Cancer Staging Handbook,
Seventh Edition (2010) [13].
2.2. Tissue microarray construction
Replicate 1-mm cores were taken from tumor, peritu-
moral, and normal surrounding stromal regions from both
TURBT and cystectomy specimens, as deﬁned by a genito-
urinary pathologist (FVL). For patients experiencing a
complete pathologic response (ypT0), ﬁbrosis at the site
of the previous diagnostic TURBT was sampled to allow
direct comparison of post-NAC tissue. See supplemental
methods for full details.
2.3. Immunohistochemical (IHC) analyses
mTOR, pmTOR, and Ki67 expression was graded in a
blinded fashion. Signal intensity (0–3: 0 for negative stain,
1 for faint/equivocal stain, 2 for moderate stain, and 3 for
intense stain) and percentage of signal coverage (0–100) of
each core were scored, and the product of the intensity and
Table 1
Clinical and pathologic demographics of patient cohort
Category N (%)*
Age
Mean (SD) 61.6 (10.4)
Median (IQR) 61.5 (56–69)
Sex
Male 46 (74)
Female 16 (26)
Race
White 54 (87)
Black 2 (3)
Other 6 (10)
Clinical stage
cT2 36 (58)
cT3 18 (29)
cT4 8 (13)
Clinically node positive 10 (16)
Chemotherapy
GC 30 (48)
MVAC 10 (16)
ddMVAC 12 (19)
Other 10 (16)
Pathologic stage
ypT0 15 (24)
ypTa/ypTIS/ypT1 17 (27)
ypT2-4/ypTanyNþ 30 (48)
Pathologically node positive 11 (18)
Clinical to pathologic stage comparison
No change 9 (15)
Up-staged 18 (29)
Down-staged 35 (56)
SD ¼ standard deviation; IQR ¼ interquartile range; GC ¼
gemcitabine, cisplatin; MVAC ¼ methotrexate, vinblastine, doxorubicin
(Adriamycin), cisplatin; dd ¼ dose-dense; other chemotherapy: gemcita-
bine, carboplatin.
*All values in parenthesis are % unless otherwise noted. Clinical and
pathological staging refers to AJCC Cancer Staging Handbook, Seventh
Edition (2010).
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The score for each sample was an average of duplicated
cores of each patient. See supplemental methods for full
details.
2.4. mRNA expression analysis
To interrogate drivers and effectors of mTOR pathway
activation, we performed whole transcriptome analysis on
formalin-ﬁxed, parafﬁn-embedded tumor tissues (N ¼ 26
nonresponders at TURBT, N ¼ 22 nonresponders at
cystectomy). See supplemental methods for full details.
We evaluated differentially expressed genes (Po 0.05) in
cystectomy specimens compared with TURBT specimens in
our UW cohort and then validated these ﬁndings in a multi-
institutional cohort (metaset) consisting of 103 paired
TURBT and cystectomy specimens [11]. These data are
accessible through the NCBI Gene Expression Omnibus
Series accession number GSE87304 (TURBT).
2.5. Statistical analyses
Student’s t-test and Chi-square tests were utilized to
compare dependent variables as appropriate. One-way
ANOVA and post hoc Bonferroni tests were used to
compare means for 3 or more groups. Spearman correlation
of mTOR staining with Ki67 in tumor cells was performed
with Student’s t-tests. Analyses were performed using
GraphPad Prism version 6.0 (GraphPad Software, La Jolla,
CA) and Stata 14 (Stata, Inc., College Station, TX), with
statistical signiﬁcance set at Po 0.05. Genomic analysis on
our cohort and the validation cohort was performed using R
version 3.3.3 with signature scores calculated as the median
of mRNA expression. The heatmap.3 function plotted
representative heatmaps using median centered expression
values ranging from −1.5 to 1.5.3. Results
3.1. Patient demographics and clinicopathologic results
We identiﬁed 62 patients with UC who had paired, pre-
NAC TURBT and post-NAC cystectomy specimens avail-
able. Demographics of the cohort are shown in Table 1. All
patients had UC (N ¼ 54 with pure histology) with 8
patients having components of variant histology which did
not inﬂuence response rates. Further, 89% of patients (N ¼
55) received a complete course of full dose chemotherapy,
while 7 had level dose reductions. Ten patients (16%)
received gemcitabine and carboplatin as their primary mode
of chemotherapy. The mean and median number of lymph
nodes removed on standard dissection was 18 (standard
deviation 9) and 17 (interquartile range 11–24).
The clinical and pathological staging of all patients is
summarized in Table 1. Most patients presented with cT2disease (58%, N ¼ 36). Final pathologic evaluation revealed
15 complete responders (ypT0, 24%), 17 partial responders
(ypTa/ypTIS/ypT1, 27%), and 30 nonresponder patients (ypT2–
4/ypTanyNþ, 48%) (Table 1 and accompanying Figures). We
found no overall differences in pathologic outcomes based on
the chemotherapy regimen received (P ¼ 0.22). At the time of
this analysis, mean and median length of follow up was 37.5
months (standard deviation 30.6 months) and 36.5 months
(Interquartile range: 8–55 months), respectively. We found 12
cases of recurrent UC and 16 all-cause deaths during this
follow-up period. There were no statistically signiﬁcant differ-
ences in recurrence rates between response groups, though
recurrence was numerically more common in nonresponders
(N ¼ 9, 30%) vs. complete responders (N ¼ 2, 13%;
P ¼ 0.105, Chi-square test). Median time to recurrence in
nonresponder patients was 9 months (IQR: 3–12 months).
When evaluating mTOR and pmTOR protein expression
speciﬁcally, only a small subset of patients had both complete
mTOR expression data (TURBT and cystectomy) and long-
term follow up, precluding a robust survival analysis.
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Fig. 1. mTOR tumor protein expression is elevated in nonresponder (ypT2-4/ypTanyNþ) patients with viable tumor at cystectomy. Tumor mTOR expression
is increased in cystectomy vs. TURBT samples (A) while individual patient plots (B) show elevated/sustained level of mTOR in post-NAC tumors at
cystectomy. pmTOR tumor expression was also sustained in nonresponders (C). The 2 nonresponder patients who were pT0, Nþ are excluded from tumor
staining analysis. Statistical signiﬁcance is set at P o 0.05.
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nonresponders and sustained with increasing pathologic
stage
Baseline levels of mTOR, pmTOR, and Ki67 index in
pre-NAC TURBT specimens were similar for all stages at
diagnosis (Supplemental Table S1A and Supplemental
Figure S1A). When evaluating nonresponder patients with
viable tumor present (ypT2–4), we found signiﬁcantly
elevated tumoral mTOR expression in the post-NAC
samples compared with pre-NAC TURBT tumor samples
(Figure 1A; P ¼ 0.006). Figure 1B reveals individual,
matched patient plots of pre-NAC TURBT and post-NAC
cystectomy mTOR tumor staining. Figure 1C reveals a
sustained level of pmTOR expression in post-NAC tumors
(NS). Pre-NAC mTOR protein expression in nonresponders
was positively correlated with proliferation (as assessed by
Ki67 staining, Pearson R ¼ 0.4, P ¼ 0.04) but this
correlation was lost in post-NAC specimens (Pearson R ¼
0.1, P ¼ 0.6). Pre-NAC Ki67 index was comparable for all
tumors stratiﬁed by subsequent pathological stages
(Supplemental Figure S1B). In general, proliferation was
sustained in nonresponders (Supplemental Figure S1C).
Taken together, these data reveal an increased mTOR
protein expression in the tumor of those with no response
to chemotherapy, while pmTOR was sustained, suggesting
pathway activity with aggressive disease.
3.3. mTOR IHC expression is increased in the surrounding
tumor stroma and associated with higher pathologic stage
Baseline levels of mTOR and pmTOR in pre-NAC
TURBT samples were similar in peritumoral and normal
surrounding stroma for all stages at diagnosis
(Supplemental Table S1B and C). In the peritumoral
samples, both mTOR and pmTOR protein expression was
sustained in partial and nonresponder patients (Figures 2
and 3), whereas both mTOR (P = 0.01) and pmTOR (P =
0.03) expression was signiﬁcantly decreased in complete
responders (Figure 3). Eight of 11 patients (73%)demonstrated a complete loss of mTOR expression in the
peritumoral stroma after NAC (Table 2). Similarly, in
normal stroma, sustained mTOR and pmTOR protein
expression was detected in those with more aggressive
pathology at cystectomy, while there was essentially
no mTOR activity in complete responders (Figure 4).
Overall, we reveal a stage dependent, sustained
mTOR protein expression in the peritumoral and normal
surrounding stroma of post-NAC patients, suggesting
mTOR activity in the tumor microenvironment reﬂects
treatment response.
3.4. Genes associated with mTOR activity are up-regulated
in the tumors of chemotherapy resistant, nonresponding
patients
Whole transcriptome analysis revealed 74 genes that are
signiﬁcantly up-regulated in the tumors of nonresponder
patients after NAC (cystectomy vs. TURBT, Po 0.05,
Supplemental Table S2). Five out of the top 20 up-
regulated, protein-coding genes were relevant to mTOR
pathway activation (Figure 5A, Supplemental Table S2).
Genes activating the mTOR pathway include thrombospon-
din (THBS1, P ¼ 0.006) and ﬁbronectin 1 (FN1, P ¼
0.029). THBS1 is a multimodular protein associated with
the extracellular matrix which is postulated to promote
chemotherapy resistance through activating the ß1/mTOR
pathway via p70S6K and S6RP phosphorylation and is
associated with increasing pathologic stage in breast cancer
[16]. FN1 is a glycoprotein on the cell surface, involved in
adhesive and migratory processes of cells, which has been
linked to increased cellular proliferation and invasion
through phosphorylation of mTOR and 4E-BP1 signaling
mechanisms [17]. Up-regulated genes, downstream of
mTOR include the human oncogene c-fos (FOS, P ¼
0.016), calponin 1 (CNN1, P ¼ 0.017), and collagen, type
I, alpha-2 (COL1A2, P ¼ 0.021). FOS is regulated by
mTOR and is a major component of the activator protein-1
(AP-1) transcription factor complex involved in cytokine
expression and immune response [18]. CNN1 is a smooth
100um
ypT0
ypT2-4/
ypTanyN+
TURBT Cystectomy
Fig. 2. Peritumoral mTOR expression is lost in complete responder patients (ypT0). Representative images showing the peritumoral expression of mTOR is
decreased/lost in complete responders (ypT0, top right panel) but sustained in nonresponders (ypT2-4/ypTanyNþ, bottom right panel) after NAC. Red arrow:
mTOR-positive stromal cells. Tumor is outlined by dotted line.
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by rapamycin in the bladder [19]. Finally, COL1A2 is a
collagen type I marker regulated by mTOR [20]. In our
cohort of nonresponders, expression of this 5-gene signature
was higher in cystectomy vs. TURBT specimens, though
this did not reach statistical signiﬁcance (P ¼ 0.15,
Figure 5B, left). However, with an increase in sample size,
using the validation cohort, this signature was signiﬁcantly0
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Fig. 3. mTOR and pmTOR protein expression in the peritumoral stroma shows
pmTOR (right panel) protein expression is decreased in complete responders (ypT
ypTanyNþ). Statistical signiﬁcance is set at Po 0.05; NS: nonsigniﬁcant.overexpressed in cystectomy specimens (Po 0.001,
Figure 5B, right).4. Discussion
We performed the ﬁrst evaluation of mTOR protein
expression in both the tumor and its microenvironment in0
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differential activity based on stage at cystectomy. mTOR (left panel) and
0), but sustained in partial (ypTa/ypTIS/ypT1) and nonresponders (ypT2-4/
Table 2
mTOR and pmTOR expression loss in tumor stroma postchemotherapy at
cystectomy
mTOR pmTOR
Peritumoral
stroma
Normal
stroma
Peritumoral
stroma
Normal
stroma
ypT0 8/11 (73%) 4/8 (50%) 4/9 (44%) 4/6 (67%)
ypTa/ypTIS/
ypT1
2/8 (25%) 1/6 (17%) 2/8 (25%) 5/6 (83%)
ypT2-4/
ypTanyN+
6/18 (33%) 1/7 (14%) 3/17 (18%) 5/7 (71%)
Note: The table represents only patients who demonstrated a detectable
expression at TURBT and a complete loss of expression at cystectomy.
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24% (N ¼ 15) experienced a complete pathologic response
(ypT0), while nearly half were nonresponders to NAC
(ypT2–4/ypTanyNþ, 48%, N ¼ 30). We found that tumor
mTOR protein expression was signiﬁcantly increased at
cystectomy (compared with TURBT samples) in nonres-
ponder patients. Interestingly, we also show that mTOR
expression in the tumor microenvironment is sustained in
the nonresponders but largely abated in the complete
responders, suggesting inﬂuence from the tumor micro-
environment on invasive UC. We evaluated transcriptomic
expression data associated with mTOR activation in treated
tumors, ﬁnding consistent up-regulated genes in both our
cohort and an external validation cohort. These ﬁndings
highlight mTOR activation in pathologically aggressive
UC, which involves the tumor microenvironment, and
supports the continued relevance of targeting mTOR in
bladder cancer.
Initial mTOR work by Mansure and colleagues,
revealed RAD001 (Everolimus) inhibited proliferation in
urothelial carcinoma cell lines and xenografts [21]. Study0
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Fig. 4. mTOR and pmTOR protein expression in the normal surrounding stroma
and pmTOR (right panel) protein expression in the normal surrounding stroma i
ypTIS/ypT1) and nonresponder patients (ypT2-4/ypTanyNþ). Arrow denotes 1 p
score ¼ 120) with near complete response at cystectomy (H-score ¼ 10). Statiof mTOR protein expression by Hansel et al. implicated
pmTOR as a marker of pathway activation in UC,
revealing that it corresponds with increased pathologic
stage at cystectomy, is associated with increased invasion
in vitro, can be inhibited in a dose-response manner by
rapamycin in cell lines, and reduces tumor growth in
xenografts [22]. Our data adds signiﬁcantly to this by
conﬁrming that mTOR protein expression is associated
with increased aggressiveness, while revealing the novel
ﬁnding of sustained mTOR activity in the tumor micro-
environment. Additionally, we found multiple up-regulated
genes relevant to mTOR activity, in patients with more
aggressive pathology at cystectomy, a known surrogate for
worsened cancer survival. These up-regulated genes
included an important growth transcription factor (FOS),
as well as genes involved in the extracellular matrix
(THBS1, FN1, COL1A2) and bladder smooth muscle
(CNN1), the latter of which likely contribute to the tumor
microenvironment. These combined IHC and RNA expres-
sion data suggest the complexity of UC and a proposed
need to consider treating the entire tumor environment, in
order to decrease chemoresistance for cisplatin-based
chemotherapy [5].
The role of the tumor microenvironment in treatment
resistance is an active area of study. Previous authors from
our institution have discussed the role of DNA damage
response and the DNA secretory program’s role in treat-
ment resistance [7,8] as well as the critical role of the
mTOR pathway [9]. Our results reveal that, in chemo-
resistant patients, increased mTOR activity is present in
both the tumor and its microenvironment. The selection
pressures for this chemoresistance are likely contributed to
by the genotoxic stress response and resistant pathways
exercised by aggressive UC [7–9]. Genomic subtyping of
UC has the potential to improve the overall treatment
landscape and initial experiments interrogating speciﬁc
components of the mTOR pathway relative to these0
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Fig. 5. Differentially expressed protein-coding genes relevant to the mTOR pathway are found in nonresponder (ypT2-4/ypTanyNþ) patients. Transcriptome
analysis of the top 20 up-regulated protein-coding genes revealed 5 genes, relevant to mTOR activity, that were up-regulated at cystectomy in nonresponders
patients in both the UW cohort and validation metaset (A; red: up-regulated; blue: down-regulated). A signature score of the 5 mTOR-associated genes in RC
vs. TURBT samples was calculated (B; error bars represent mean ± SEM) revealing increased expression in the cystectomy samples of nonresponder patients.
Statistical signiﬁcance is set at Po 0.05.
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selective mutations in the mTOR pathway (e.g., TSC)
have shown encouraging inﬂuence on treatment sensitivity
[24]. However, the clear real-world efﬁcacy of mTOR
inhibition in UC remains elusive [25,26]. Ongoing trials
focusing on mTOR inhibition hold promise (e.g.,
NCT01182168 and NCT01182168) but the complex
interplay of factors inherent to the tumor microenviron-
ment signal the need for more comprehensive research.
Prospective studies targeting mTOR [4,27] as well as
other compensatory resistance pathways, particularly in
the tumor microenvironment, will improve understanding
of treatment resistance and therapeutic efﬁcacy
in UC.
Limitations to this study include the retrospective
design and patient selection from a single institution. All
pathologic samples obtained were subject to individual
storage methods and ranged in time from acquisition,
which may have inﬂuenced quality of the cores for TMA
creation. IHC analysis is limited by the inability to
evaluate tumor mTOR expression in the “complete” and
“partial responder” groups, due to the ablation of tumor
cells. Further, assessing biomarkers from TMA has its
inherent limitations in terms of small representation of the
tumor and the lack of tumor heterogeneity on a particular
core. From a clinical perspective, there may be some
heterogeneity in the TURBT specimens acquired by out-
side providers given the referral nature of our institution.
Finally, given the small sample size and the nature of this
retrospective study, robust, long-term recurrence and
survival analysis was not possible. Our report of sustainedmTOR protein expression in the tumor microenvironment
of nonresponder UC patients and whether this expression
has deﬁnitive implications for recurrence and prognosis,
requires further study.5. Conclusions
This study is the ﬁrst to evaluate mTOR protein
expression in the tumor microenvironment of UC, before
and after NAC. Our results show that mTOR protein
expression is signiﬁcantly increased in tumor and sustained
in the tumor microenvironment of patients with adverse
pathologic ﬁndings at cystectomy. Transcriptome analysis
revealed multiple up-regulated genes relevant to mTOR
pathway activity. Together, these results suggest the con-
tinued relevance of targeting this pathway in urothelial
carcinoma.Source of funding
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